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Abstract
Purpose. Angiosarcoma is a rare tumor with endothelial cell differentiation that may arise in any anatomic location.The
purpose of this report was to identify prognostic factors on outcome in a group of prospectively followed patients with
con® rmed angiosarcoma.
Subjects. Adult patients (>16 years old) with angiosarcoma treated between July 1982 and February 1998 were identi® ed
from a prospective database.
Methods. Pathologic con® rmation of all cases was performed prior to inclusion in this analysis. Various prognostic factors
were evaluated for disease-speci® c survival. Survival was determined by the Kaplan± Meier method. Statistical signi® cance
was evaluated by log-rank test for univariate analysis and Cox stepwise regression for multivariate analysis (p<0.05).
Results. Fifty patients were identi® ed; at the initial evaluation, this group included 32 patients with a primary tumor, three
with local recurrence and 15 with metastatic disease. Tumor sites included 16 head and neck and skin of head, eight
extremity, seven trunk, six breast, ® ve pelvis, four viscera and four thoracic. Median follow-up among survivors was 71
months (range, 38± 191 months).Two- and 5-year disease-speci® c survival was 50 and 30%, respectively, with a median of
24 months. The factor predictive of tumor-related mortality was presentation status (p=0.001; relative risk, 5). Two-year
disease-speci® c survival for patients presenting with recurrent or metastatic disease was 13%, compared with 70% for those
with primary disease.
Discussion. Angiosarcoma is an aggressive sarcoma with high metastatic potential and subsequent mortality. Patients with
primary angiosarcoma demonstrate a survival advantage compared with patients with metastatic disease. Enrollment in
investigational trials for high-risk patients with recurrent or metastatic disease is recommended to potentially improve
survival.
Introduction
Vascular sarcomas are uncommonvasoformative soft
tissuetumors.Historically,angiosarcoma,lymphangi-
osarcoma and hemangiopericytoma have been
grouped under the heading of vascular soft tissue
sarcomas.
1 Hemangiopericytoma is thought to arise
from specialized smooth muscle cells termed `Peri-
cytes of Zimmerman’ that surroundblood vessels.In
contrast, angiosarcoma and lymphangiosarcoma
demonstrateendothelialcelldifferentiation.Pathologi-
cally, there is no difference between angiosarcoma
and lymphangiosarcoma, a tumor whose distinction
is based on its clinical presentation, and both are
includedin this study.Epithelioid hemangioendothe-
lioma
2isa morerecentlydescribedmalignant vascular
tumor that, from preliminary statements,
3 seems to
follow a less malignant course than angiosarcoma
and is not included in the present analysis.
Angiosarcomarepresentsabout2% of all soft tissue
sarcomas.
4 At the time of diagnosis, 10± 25% of
patients already have metastatic disease.
4 Angiosar-
coma may originate from any anatomic site,although
the most common sites are the skin of the head and
neck, extremities, trunk and breast;
4,5 but angiosar-
coma of the liver, lungs,heart, pelvis and retroperito-
neum has also been reported. The development of
angiosarcoma in patients undergoing prior irradia-
tion,
6 toxic chemical exposure, Stuart± Treves
syndrome and other malignancies
4,7 has been
documented but, for the majority of patients, no
speci® c risk factors are identi® ed. Similarly, limited
information is available on prognostic factors that
affect outcome for patients with angiosarcoma.
Methods
A prospective database of adult patients (older than
16 years) with soft tissue sarcoma, admitted and
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Center, was established in July 1982. The database
contained 73 patients who underwent treatment for
angiosarcomaincludinglymphangiosarcomabetween
July 1982 and February 1998.
Inclusioninto this analysis was restricted to patients
with a con® rmed diagnosis of angiosarcoma or
lymphangiosarcoma; pathologic assessment was
conducted by three experienced soft-tissue sarcoma
pathologists (J.M.W., C.A., J.X.). Only those cases
with a unanimousagreementas to the diagnosis were
included in this analysis. In 15/73 cases, pathological
material was notavailable or was insufficientfor evalu-
ation. Five out of 73 patients had tumors that were
considered undifferentiated sarcomas, 1/73 had an
epithelioid hemangioendothelioma,and 2/73 patients
had benign vascular tumors.The remaining 50 cases
form the basis of this report.
Clinical and pathologic variables were correlated
with survival endpoints. Various chemotherapy and
radiation therapy regimens were used to treat these
patients. However, over the 16-year period, differ-
ences in chemotherapy agents available, radiation
protocols, patient enrollment into clinical trials and
the geographic availability of these modalities
precludestheir analysis as a predictivefactor.Clinical
variables analyzed included:age at diagnosis (<50 or
>50 years) and sex. Tumor variables analyzed
included:microscopic margins (negative or positive),
size (<5, 5± 10 and >10 cm), depth (super® cial or
deep), and anatomic site (head and neck and skin of
head,extremity,trunk,breast,pelvis/retroperitoneum,
viscera and thoracic cavity).Tumors were considered
high grade with the exception of angiosarcomas of
the breast,which were gradedaccordingto the criteria
of Donnell et al.
8 using a three-tier grading scheme;
however, histologic grade was not a variable in this
study as there were insufficient numbers of patients
with low-grade lesions for analysis.
Survival and statistical analysis
Disease-speci® c survivalwas calculatedby the method
of Kaplan and Meier.
9 Deaths caused by the disease
were treated as an endpoint for disease-speci® c
survival. Other deaths were treated as censored
observations.
Signi® cance between survival curves of popula-
tions was evaluated using log-rank testing for
univariate in¯ uence and Cox-model stepwise regres-
sion for multivariate in¯ uence.The results of the Cox
model analysis are reported with relative risks and
con® denceintervals.Comparison between clinicaland
pathological categorical variables in different groups
was performedusing Fisher’s exact test for univariate
and multivariate logistic regression to establish
independent adverse prognostic factors for disease-
speci® c survival. In all statistical analyses, p<0.05
was considered signi® cant.
Results
Patients
Fifty patients (25 male and 25 female) were identi-
® ed. Their ages ranged from 18 to 84 years with a
median of 55 years.Fifty-eight percentof the patients
were over 50 years old. At presentation, 32 patients
(64%) had primary tumor, three (6%) had a local
recurrence and 15 (30%) had metastatic disease
(Table 1). One patient in each of the primary and
metastatic tumor presentation categories had clinical
evidence of lymphangiosarcoma.Head,neckand skin
of head (HNS) was the most common anatomic site
of disease in 16 patients (32%), followed in frequency
by the extremities in eight (16%), trunk in seven
(14%), breast in six (12%), pelvis/retroperitoneumin
® ve (10%), viscera in four (8%) and thorax in four
patients (8%).
Patients presenting with recurrence or metastasis
had a higher proportion of tumors >5 cm than those
with localized disease (12/18 versus 9/32; p=0.001).
There were 14/18 deep tumors in the former group
versus 14/32 in the latter (p=0.02).
Pathologic ® ndings
With the exception of four mammary tumors, all
angiosarcomas were high grade. The mammary
tumors showed a range of low-to high-grade angiosa-
rcoma.
Surgical resection was performed in 29/32 of the
patients presenting with primary tumor. Following
resection, six patients (20%) had positive gross
margins and 12 (41%) had positive microscopic
margins.
Table 1. Clinical characteristicsof50 patients with angiosa-
rcoma
n % of total
Primary 32 64
Local recurrence 3 6
Metastatic 15 30
Gender 25 M, 25 F
Age range (years) 18± 84
Median age (years) 55
Size
Unknown 3 6
<5 cm 29 58
‡ 5 and <10 cm 13 26
‡ 10 cm 5 10
Depth
Super® cial 22 44
Deep 28 56
Site
Head, neck and scalp 16 32
Extremities 8 16
Trunk 7 14
Breast 6 12
Pelvis/retroperitoneum 5 10
Viscera 4 8
Thoracic 4 8
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Medianfollow-up for survivorswas 71 months(range,
38± 191 months). During the follow-up period, eight
(16%) patients developed local recurrence and 14
(28%) metastases.
Of the initial 50 patients,33 (66%) patients died of
disease and seven (14%) patients died of other causes
during the follow-up period. When grouped by
presentation status,15 (44%) patients presentingwith
primary disease, three (100%) patients presenting
with a local recurrence and 15 (100%) patients
presentingwith metastatic disease succumbedto their
disease.
Survival
The 2- and 5-year overall survival was 50 and 30%,
respectively (Fig. 1), with a median overall survival
of 24 months.The 2-year disease-speci® c survival for
those presenting with locally recurrent disease was
33%, and was 13% for those presenting with metas-
tases, compared with 70% for patients presenting
with primary disease (Fig. 2).All patients with recur-
rent or metastatic angiosarcoma died, and they had
® ve times the risk of dying from disease than the
primary presenters (p=0.001). No other covariates
were found to be independent adverse prognostic
factors for disease-speci® c survival.
Discussion
Angiosarcoma of the HNS was the most frequent
anatomic site of disease in this analysis; an observa-
tion that is consistent with Western and Japanese
literature.
4,10 HNS angiosarcoma occurred in
approximately one-third of the entire patient group
(n=50), as well as in 41% of the patients in the
primary-presentation group (n=32).
Patients that presentedwith recurrentor metastatic
disease demonstrated a signi® cant decrease in overall
survival. Metastatic disease at presentation has been
a consistentfactor associated with a worsenedsurvival
for patients with angiosarcoma
5and for patients with
other sarcoma subtypes.
11± 13In this cohort,the 2-year
disease-speci® c survival for patients presenting with
recurrent or metastatic disease was 13%, compared
with 70% for those with primary disease.
Of the patients with primary disease at presenta-
tion who underwent surgical resection (n=29), six
(20%) had positive gross margins and 12 (41%) had
positive microscopic margins following resection.
These data suggest that resection of gross disease
may not achieve microscopic negative margins, since
positive microscopic margins were identi® ed twice as
often as positive gross margins.This may be due to
biologic factors such as unappreciated tumor exten-
sion or multicentric disease.
5,14 Furthermore, the
inability to achieve microscopically negative margins
for patients with angiosarcoma has been consistently
identi® ed and has been associated with an unfavo-
rable survival outcome.
13± 15 Because of the modest
size of ourcohort,we could not con® rm this observa-
tion.
Tumor extensionbeyond the primary resection site
and the need for subsequent re-resection for patients
with soft tissue sarcoma (STS) is well described.
15
Patients with STS that have undergonea prior resec-
tion and obtainednegative microscopicmargins,upon
undergoing re-resection as an oncologic principle,
may be found to have residual disease in the
Fig. 1. Kaplan± Meier 5-year overall survival (months).
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15Unfortunately,location alone
may limit the extent of the initial resection for patients
with angiosarcoma and re-resection is similarly not
feasible.
In this analysis, there was no observed signi® cant
outcomeadvantage based on tumorsite.In the group
of patients with HNS disease (n=16), 6/16 (35%)
patients developed local recurrence, two developed
metastases and 11 (65%) died of their disease. In a
previous report of patients (n=18) with angiosar-
coma of the HNS,
14 only 50% of the patients had
resectablediseaseat presentation and,followingresec-
tion,approximately 30% of these patients were found
to have positive microscopicmargins.
14The reported
overall 5-year survival in that series of patients was
33% and the factor predictive of a negative survival
was limited to size >10 cm.
The 2- and 5-year overall survival for patients with
angiosarcoma in this report (n=50) was 50 and 30%,
respectively.Angiosarcomahas been suggestedto have
the poorest prognosis among the soft tissue
sarcomas,
5,13,16 and our survival data supports this
observation. However, prolonged survival may be
achieved in selected patients;among the nine patients
who survived at least 5 years, ® ve survived longer
than 10 years (131, 146, 148, 178, and 191 months).
The patients observed to have long-term survival all
presented with surgically resectable primary tumors
of the extremities, breast and head and neck.There
were no long-term survivors in the group of patients
presentingwith primary thoracic,visceral or retroperi-
toneal disease.
Outcome for patients with STS may re¯ ect differ-
ences in surgical resection of disease, tumor grade,
the lackof efficaciousadjuvant therapy or the inherent
biologic properties of the tumor,
1,11,12,17 as has been
proposed in previous reports.The observed patterns
of diseaseprogressionin this series suggesta tendency
for metastasis rather than local recurrencefor patients
with angiosarcoma;however,factors in¯ uencinglocal
recurrence and metastatic patterns are precluded by
the modest cohort in this analysis.
Additionally, the strict pathologic review of tissue
specimens prior to inclusion into this analysis may
have also prevented the con® rmation of previously
reported prognostic factors for patients with angiosa-
rcoma.
Conclusions
Angiosarcomais an uncommontumor that is biologi-
cally aggressive, with a high metastatic potential and
subsequent mortality. Patients presenting with
primary angiosarcoma have a signi® cant survival
advantage compared with patients with recurrent or
metastatic disease. Patients with primary angiosar-
coma shouldundergosurgicalresectionfor a potential
survival advantage. Long-term survival for patients
with primary angiosarcoma undergoing resection is
possible, as evidenced by the results of this analysis.
Patients with recurrent or metastatic angiosarcoma
should be considered to be at high-risk for progres-
sion of the disease and we would recommend enroll-
ment into investigational trials to de® ne the role of
postoperative adjuvant therapies and potentially
improve survival.
Fig. 2. Kaplan± Meier 5-year survival (months) strati® ed by presentation status:dot-dashed line, metastatic presentation;dotted line,
recurrent presentation;solid line, primary presentation.
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